Xu Zhongqing, Healy James, Dong Wenhui, Ding JingJing, Shen Xiaoyi, Feng Xianzhen, Zhou Jun, Puranik Rajesh, Hambly Brett D, Bao Shisan
Department of General Practice, Tongren Hospital, Shanghai Jiao Tong University, School of Medicine, China.
Jiangnan University, Wuxi, China.
Atheroscler Plus. 2025 Aug 5;61:41-47. doi: 10.1016/j.athplu.2025.07.003. eCollection 2025 Sep.
Type 2 diabetes mellitus (T2DM) promotes atherosclerosis and plaque instability through chronic inflammation and immune dysregulation. Emerging evidence implicates members of the interleukin-1 family-particularly IL-36, IL-37, and IL-38-in the modulation of inflammatory responses in diabetic and non-diabetic vascular disease. However, their roles in carotid atherosclerosis remain poorly defined.
In this retrospective observational study, circulating cytokine levels were assessed in 20 T2DM and 40 non-DM individuals using ELISA. Carotid plaque samples (n = 50) were collected from endarterectomy procedures and categorised as stable (asymptomatic, n = 25) or unstable (symptomatic, n = 25) according to AHA criteria. Immunohistochemistry quantified local expression of IL-36α, IL-36β, IL-36γ, IL-37, and IL-38.
Circulating IL-36α, IL-36β and IL-36γ were significantly elevated in T2DM patients, while IL-37 and IL-38 levels were unchanged. Immunohistochemistry revealed significantly increased expression of all five cytokines in unstable versus stable plaques. Stratification by diabetic status showed that this upregulation was exclusive to diabetic patients. Notably, IL-36β exhibited the most pronounced increase-over 25-fold-in unstable diabetic plaques. IL-37 and IL-38 were also elevated locally, likely reflecting compensatory anti-inflammatory responses, though their circulating levels remained unaffected.
This study demonstrates differential expression of IL-36, IL-37, and IL-38 in carotid atherosclerotic plaques, with IL-36β emerging as a key pro-atherogenic cytokine in the diabetic setting. The distinct expression patterns of these cytokines in diabetic versus non-diabetic plaques suggest that T2DM exacerbates immune imbalance in atherosclerosis. These findings may inform future research on cytokine-targeted therapies for diabetic vascular complications.
2型糖尿病(T2DM)通过慢性炎症和免疫失调促进动脉粥样硬化和斑块不稳定。新出现的证据表明,白细胞介素-1家族成员——特别是IL-36、IL-37和IL-38——在糖尿病和非糖尿病血管疾病的炎症反应调节中发挥作用。然而,它们在颈动脉粥样硬化中的作用仍不明确。
在这项回顾性观察研究中,使用酶联免疫吸附测定法(ELISA)评估了20名T2DM患者和40名非糖尿病个体的循环细胞因子水平。从动脉内膜切除术采集了50个颈动脉斑块样本,并根据美国心脏协会(AHA)标准分为稳定型(无症状,n = 25)或不稳定型(有症状,n = 25)。免疫组织化学法对IL-36α、IL-36β、IL-36γ、IL-37和IL-38的局部表达进行定量分析。
T2DM患者的循环IL-36α、IL-36β和IL-36γ显著升高,而IL-37和IL-38水平未发生变化。免疫组织化学显示,与稳定斑块相比,不稳定斑块中所有五种细胞因子的表达均显著增加。按糖尿病状态分层显示,这种上调仅见于糖尿病患者。值得注意的是,IL-36β在不稳定糖尿病斑块中的增加最为显著——超过25倍。IL-37和IL-38在局部也升高,可能反映了代偿性抗炎反应,尽管它们的循环水平未受影响。
本研究证明了IL-36、IL-37和IL-38在颈动脉粥样硬化斑块中的差异表达,其中IL-36β在糖尿病环境中成为关键的促动脉粥样硬化细胞因子。这些细胞因子在糖尿病与非糖尿病斑块中的不同表达模式表明,T2DM会加剧动脉粥样硬化中的免疫失衡。这些发现可能为未来针对糖尿病血管并发症的细胞因子靶向治疗研究提供参考。